EcoDrugPlus

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSSARG00000008883
Gene Symbol: KCNMA1
1 External references
284 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSSARG00000003155
Gene Symbol: KCNJ2
1 External references
277 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSSARG00000006193
Gene Symbol: KCNJ3
1 External references
219 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 2

Ensembl ID : ENSSARG00000014238
Gene Symbol: KCNK2
1 External references
280 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSSARG00000013606
Gene Symbol: KCND3
1 External references
259 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSSARG00000008532
Gene Symbol: KCNQ3
1 External references
191 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSSARG00000002056
Gene Symbol: PSENEN
3 External references
183 Possible Orthologues:

Prostaglandin D2 Receptor

Ensembl ID : ENSSARG00000008128
Gene Symbol: PTGDR
3 External references
118 Possible Orthologues:

Prostaglandin E Receptor 2

Ensembl ID : ENSSARG00000001572
Gene Symbol: PTGER2
1 External references
241 Possible Orthologues:

Prostaglandin E Receptor 3

Ensembl ID : ENSSARG00000009446
Gene Symbol: PTGER3
1 External references
194 Possible Orthologues:

Prostaglandin F Receptor

Ensembl ID : ENSSARG00000006169
Gene Symbol: PTGFR
3 External references
195 Possible Orthologues:

Proteasome 20s Subunit Alpha 1

Ensembl ID : ENSSARG00000010022
Gene Symbol: PSMA1
1 External references
254 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).